Normal saline versus heparin solution to lock totally implanted venous access devices: Results from a multicenter randomized trial

被引:25
作者
Dal Molin, Alberto [1 ]
Clerico, Mario [2 ]
Baccini, Michela [3 ,4 ]
Guerretta, Linda [2 ]
Sartorello, Barbara [2 ]
Rasero, Laura [5 ]
机构
[1] Univ Piemonte Orientale, Biella Hosp, Sch Nursing, Biella, Italy
[2] Oncol Ctr Biella, Biella, Italy
[3] Univ Florence, Dept Stat Informat & Applicat, Florence, Italy
[4] ISPO Canc Prevent & Res Inst, Biostat Unit, Florence, Italy
[5] Univ Florence, Florence, Italy
关键词
Flushing; Heparin; Normal saline; Nursing; CATHETER; COMPLICATIONS; MANAGEMENT; PORTS; METAANALYSIS; ONCOLOGY; PATENCY;
D O I
10.1016/j.ejon.2015.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Our aim was to determine the non-inferiority of normal saline flushing compared to heparin flushing in maintaining the patency of totally implanted venous access devices (TIVADs). Method: Four hundred and thirty patients were recruited from 14 Italian centres. Patients were randomized to heparin group or to normal saline group. The primary outcome of the study was TIVAD occlusion. Results: After randomisation, 203 patients were assigned to normal saline group and 212 to heparin group. Median follow up time was 204 days in normal saline group and 294 in the heparin group. We observed 24 withdrawal occlusions (5.78%): 10 in the heparin group and 14 in the normal saline group. One total occlusion was observed in the normal saline group. Taking as reference the arm treated with heparin, the absolute risk difference was 2.67 with the 90% Cl including the non inferiority margin of 4%. No significant difference between hazards of occlusion was found. Conclusions: This study failed to demonstrate that normal saline flushing is not inferior to heparin flushing, even if a significant difference between the two treatments was not found. The use of heparin is controversial and other prospective trials are necessary in this field. Trial registration: EudraCT number: 2009-013620-22. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:638 / 643
页数:6
相关论文
共 27 条
[1]  
[Anonymous], CAR MAINT RED VASC A
[2]   Totally implantable central venous access ports for long-term chemotherapy - A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days [J].
Biffi, R ;
de Braud, E ;
Orsi, E ;
Pozzi, S ;
Mauri, S ;
Goldhirsch, A ;
Nole, F ;
Andreoni, B .
ANNALS OF ONCOLOGY, 1998, 9 (07) :767-773
[3]   Prospective, Randomized Trial of Two Different Modalities of Flushing Central Venous Catheters in Pediatric Patients With Cancer [J].
Cesaro, Simone ;
Tridello, Gloria ;
Cavaliere, Mara ;
Magagna, Laura ;
Gavin, Patrizia ;
Cusinato, Riccardo ;
Zadra, Nicola ;
Zanon, Giovanni Franco ;
Zanesco, Luigi ;
Carli, Modesto .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2059-2065
[4]  
Dal Molin A, 2009, Minerva Pediatr, V61, P549
[5]   The management of totally implanted venous ports in the ambulatory oncologic patient [J].
Dal Molin, A. ;
Guerretta, L. ;
Mazzufero, F. ;
Rasero, L. .
JOURNAL OF VASCULAR ACCESS, 2009, 10 (01) :22-26
[6]   Flushing the central venous catheter: is heparin necessary? [J].
Dal Molin, Alberto ;
Allara, Elias ;
Montani, Doriana ;
Milani, Simona ;
Frassati, Cristina ;
Cossu, Simonetta ;
Tonella, Simone ;
Brioschi, Dania ;
Rasero, Laura .
JOURNAL OF VASCULAR ACCESS, 2014, 15 (04) :241-248
[7]   Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study [J].
Dal Molin, Alberto ;
Di Massimo, Dino Stefano ;
Braggion, Cesare ;
Bisogni, Sofia ;
Rizzi, Elena ;
D'Orazio, Ciro ;
Di Toppa, Maria Vittoria ;
Alghisi, Federico ;
Cristadoro, Simona ;
Carnovale, Vincenzo ;
Festa, Gabriella ;
Rampini, Serena ;
Colombo, Carla ;
Oneta, Anna ;
Furnari, Maria Lucia ;
Calamia, Maria Antonietta ;
Zunino, Maria Luisa ;
Tuccio, Giuseppe ;
Spadea, Vincenzo ;
Messore, Barbara ;
Grosso, Bianca ;
Festini, Filippo .
JOURNAL OF VASCULAR ACCESS, 2012, 13 (03) :290-295
[8]   Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation [J].
Garajova, I. ;
Nepoti, G. ;
Paragona, M. ;
Brandi, G. ;
Biasco, G. .
EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (01) :125-132
[9]  
GOODE CJ, 1991, NURS RES, V40, P324
[10]   Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial [J].
Goossens, G. A. ;
Jerome, M. ;
Janssens, C. ;
Peetermans, W. E. ;
Fieuws, S. ;
Moons, P. ;
Verschakelen, J. ;
Peerlinck, K. ;
Jacquemin, M. ;
Stas, M. .
ANNALS OF ONCOLOGY, 2013, 24 (07) :1892-1899